Acute Myeloid Leukemia, Cardio-vascular Surgery, Myelodysplastic Syndromes
Conditions
Keywords
Myelodysplastic Syndromes, Acute Myeloid Leukemia, Bone Marrow, Mesenchymal stromal cell, Healthy donor
Brief summary
It is of clinical significance to better characterize the intrinsic defects harbored by mesenchymal stromal cells (MSC) in Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) context, as compared to physiological conditions. Such research initiative aims to dissect the cross-talk between malignant hematopoietic stem cells (HSC) and their bone marrow (BM) partners in crime, further prospecting for innovative stromal-directed strategies for the treatment of Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).
Detailed description
Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal malignancies that are characterized by ineffective hematopoiesis, progressive bone marrow failure, cytogenetic and molecular abnormalities, and increased risk for progression to acute myeloid leukemia (AML). It is a well-accepted theory that MDS and AML originate from primary alterations of hematopoietic stem cells (HSC) compartment, which confer a survival advantage to them at the expense of physiological hematopoiesis. More recently, there is growing evidences regarding the contribution of the bone marrow (BM) microenvironment to the pathogenesis of MDS and AML. Of particular interest, several studies have pointed towards a pivotal role of mesenchymal stromal cells (MSC), one of the main components of the BM niche, in the initiation and propagation of myeloid disorders. In this context, it is of clinical significance to better characterize the intrinsic defects harbored by MSC in MDS and AML context, as compared to physiological conditions. Such research initiative aims to dissect the cross-talk between malignant HSC and their BM partners in crime, further prospecting for innovative stromal-directed strategies for the treatment of MDS and AML.
Interventions
OTHERBone marrow analyses
This is a non-interventional study for the constitution of a biobank of bone marrows, in order to further investigate in vitro the cellular properties of bone marrow-isolated mesenchymal stromal cells.
Sponsors
Institut de Cancérologie de la Loire
Centre Hospitalier Universitaire de Saint Etienne
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
50 Years to 80 Years
Healthy volunteers
Yes
Inclusion criteria
* Patients with diagnosed myelodysplasia or acute myeloid leukemia (study place: ICLN) - Specific to the cases cohort * Age-matched healthy donors undergoing a cardiovascular surgery - Specific to the control cohort * Signed written informed consent form * Patient affiliated to a social security regimen or beneficiary of the same
Exclusion criteria
* Medical history of hematological disorders * Thrombocytopenia, anemia… * Patient under guardianship or deprived of his liberty or any condition that may affect the patient's ability to understand and sign the informed consent (art. L.1121-6, L.112-7, L.1211-8, L.1211-9) * Pregnant or breastfeeding women * Refusing participation
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Changes in cellular properties of mesenchymal stromal cells | Day 0 | Changes in cellular properties of mesenchymal stromal cells isolated from bone marrow aspirates by comparing normal cells (i.e. healthy donors) and MDS/AML cells. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of differential biomarkers in mesenchymal stromal cells | Day 0 | Number of differential biomarkers expressed by MDS or AML-derived mesenchymal stromal cells |
Countries
France
Outcome results
None listed